FDA
-
-
-
-
-
-
-
Neurocrine completes $2.9 billion acquisition of Soleno Therapeutics
-
-
-
-
-
-
-
Neurocrine begins phase 1 trial of obesity drug targeting new mechanism
-
-
-
-
-
-
-
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adre
-
-
-
-
-
-
-
Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio
-
-
-
-
-
-
-
Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026
-
-
-
-
-
-
-
Neurocrine KINECT study fails to meet primary endpoints for cerebral palsy
-
-
-
-
-
-
-
Where can biotech stocks go from here? RBC answers
-
322,218 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

